Sign in →

Test ID SFLB Influenza Virus B Antibodies, IgG and IgM (Separate Determinations), Serum

Reporting Name

Influenza Virus B Ab, IgG, IgM, S

Useful For

Diagnosis of recent infection by influenza virus type B when isolation of the organism by culture is unsuccessful

Specimen Type


Specimen Required

Preferred: Serum gel

Acceptable: Red top

Specimen Volume: 0.25 mL

Collection Instructions: Indicate influenza virus B.

Specimen Minimum Volume

0.15 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 14 days
  Frozen  14 days

Reference Values

IgG: <1:10

IgM: <1:10

Reference values apply to all ages.

Day(s) and Time(s) Performed

Tuesday, Friday; 9 a.m.

Test Classification

This test has been cleared, approved or is exempt by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86710 x 2

LOINC Code Information

Test ID Test Order Name Order LOINC Value
SFLB Influenza Virus B Ab, IgG, IgM, S In Process


Result ID Test Result Name Result LOINC Value
5733 Influenza Virus B Ab, IgG 9535-6
5734 Influenza Virus B Ab, IgM 9536-4

Clinical Information

Influenza is usually a mild illness of the upper respiratory tract. Involvement of the lower respiratory tract, however, can lead to 4 types of clinical syndromes; physical signs of lower respiratory tract involvement without roentgenographic evidence of pneumonia, influenza complicated by bacterial pneumonia, primary influenza virus pneumonia, and combined influenzal and bacterial pneumonias. Incidence of influenza virus infections is seasonal in the United States and usually occurs only from November to March.


Influenza virus infections are most severe in patients with certain preexisting conditions such as rheumatic heart disease, bronchopulmonary disease, impaired renal function, and diabetes mellitus. Infections can be more severe in elderly patients, pregnant females, and immunocompromised patients.


Influenza virus type B generally produces less severe disease than type A. Outbreaks of influenza type B virus are usually more localized than type A. Both infections occur in the United States between November and March.


Influenza A is susceptible to antiviral activity of amantadine while influenza B is not inhibited by this drug.


The presence of IgM class antibody or a 4-fold or greater rise in titer in paired (acute and convalescent) sera indicates recent infection.


The presence of IgG class antibody alone generally indicates past exposure.

Clinical Reference

1. Rothbarth PH, Groen J, Bohnen AM, et al: Influenza virus serology-a comparative study. J Virol Methods 1999;78:163-169

2. Pachucki CT: The diagnosis of influenza. Semin Resp Infect 1992;7:46-53

3. Wendt CH: Community respiratory viruses: organ transplant recipients. Am J Med 1997;102:31-36:42-43

Analytic Time

1 day

Method Name



If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.